课题基金 / 基金详情

Establishment of neuroblastoma regression model and molecular mechanisms

Establishment of neuroblastoma regression model and molecular mechanisms
神经母细胞瘤消退模型的建立及分子机制
批准号:
14570164
负责人:
HATA Jun-ichi
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

HATA Jun-ichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Schwannian stroma in neuroblastomas is related to the prognosis of patients with neuroblastoma. There is debate surrounding the origin of Schwannian stroma in neuroblastomas : one theory being that the Schwann cells are derived from neoplastic cells, and the other that they arise from normal cells surrounding the neuroblastoma. We examined whether human bone marrow stromal cells (hBMSC) or human mesenchymal stem cells (hMSCs) differentiated into Schwann cells in neuroblastomas. HBMSCs or hMSCs with enhanced green fluorescent protein (EGFP) were injected into xenotransplanted neuroblastomas in non-obese diabetic mice with severe combined immunodeficiency and the resulting tumor analyzed using immunohistochemistry. HBMSCs or hMSCs were also co-cultured with neuroblastoma cells, and the induction of Schwann cell-specific molecules, S100beta and Egr-2, was monitored. S100beta-positive Schwannian stroma was only observed in the neuroblastomas containing hBMSCs or hMSCs, and not in the neuroblastomas without hBMSCs or hMSCs. Double-staining with anti-S100 and anti-EGFP showed that S100-positive cells in neuroblastomas were also EGFP-positive. By contrast, hBMSCs didn't develop into Schwann cells in Ewing's sarcoma. These results showed the transplanted hBMSCs or hMSCs differentiated into Schwann cells specifically in neuroblastomas. S100beta and Egr-2 were expressed in hBMSCs or hMSCs co-cultured with neuroblastoma cells. HBMSCs or hMSCs may contribute to the formation of human tumor stroma and the Schwannian stroma of neuroblastomas may be derived from non-neoplastic stromal cells.
期刊论文(76)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/sj/bjc/6600231
发表时间: 2002-04-08
期刊: BRITISH JOURNAL OF CANCER
影响因子: 8.8
作者: [Ikeda, H, Iehara, T, Takamatsu, H]
通讯作者: Takamatsu, H
fukuma, M., Abe, H., Okita, H., Yamada T., Hata, J.: "Monoclonal antibody,4C4-mAb, specifically recognizes keratan sulfate proteog lycan on human embryonal carcinoma cells"J Pathol. (in press). (2003)
fukuma, M.、Abe, H.、Okita, H.、Yamada T.、Hata, J.:“单克隆抗体,4C4-mAb,特异性识别人胚胎癌细胞上的硫酸角质素蛋白聚糖”J Pathol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shibata, R., Umezawa, A., Takehara, K., Aoki, D., Nozawa.S., Hata, J.: "Primary carcinosarcoma of the vagina"Pathol Int. 53. 40-44 (2003)
Shibata,R.,Umezawa,A.,Takehara,K.,Aoki,D.,Nozawa.S.,Hata,J.:“阴道原发性癌肉瘤”Pathol Int。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kakimoto, T., Hattori, Y., Okamoto, S., Yamada, T.et al.: "Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome"Jpn J Cancer Res. 93. 1029-103
Kakimoto, T.、Hattori, Y.、Okamoto, S.、Yamada, T.等人:“沙利度胺治疗难治性多发性骨髓瘤:沙利度胺和血管生成因子的血浆浓度与临床结果的关系”Jpn J Cancer
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
34
    Development of novel humanized-mice and application to regenerative medicine
    Molecular Pathology of Solid Tumors in Childhood
    • 批准号:
      10307004
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $24.64万
    • 财政年份:
      1998
    • 负责人:
      HATA Jun-ichi
    • 依托单位:
    Molecular and Cell Biological Differentiation Capabilities on Human Germ Cell Tumor Cells
    • 批准号:
      03454174
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $2.94万
    • 财政年份:
      1991
    • 负责人:
      HATA Jun-ichi
    • 依托单位:
    海外基金